Live
- PM Modi highlights govt's efforts to make Odisha prosperous and one of the fastest-growing states
- Hezbollah fires 200 rockets at northern, central Israel, injuring eight
- Allu Arjun's Family Appearance on Unstoppable with NBK Breaks Viewership Records
- Unity of hearts & minds essential for peace & progress, says J&K Lt Governor
- IPL 2025 Auction: I deserve Rs 18 cr price, says Chahal on being acquired by Punjab Kings
- EAM Jaishankar inaugurates new premises of Indian embassy in Rome
- Sailing vessel INSV Tarini embarks on second leg of expedition to New Zealand
- Over 15,000 people affected by rain-related disasters in Sri Lanka
- IPL 2025 Auction: RCB acquire Hazlewood for Rs 12.50 cr; Gujarat Titans bag Prasidh Krishna at Rs 9.5 crore
- Maharashtra result reflects the outcome of Congress' destructive politics: BJP's Shazia Ilmi
Strides Pharma gets USFDA nod to market HIV drugHIV drug
Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
New Delhi: Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Singapore-based Strides Pharma Global, a stepdown wholly-owned subsidiary of the company, has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the US Food & Drug Administration (USFDA), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US. Shares of Strides Pharma Science ended 2.51 per cent up at Rs 508.20 apiece on the BSE on Wednesday
